Importantly, the combination of KRAS ASO and immRNA delivered by RBCEVs induced synergistic activation of RIG-I, leading to robust induction of tumor cell death and upregulation of IFNs in KRAS-dependent cancers both in vitro and in vivo. Here, KRAS is linked to neoplasm.